



EXPRESS SCRIPTS®

PBM Agreement Service Addendum

Date of PBM Agreement: 1/1/2022

Client Name: Boon Chapman Midland County ("Sponsor")

Carrier: 9846 **BPL/Contract:** _____ **Group:** _____

Effective Date of Addendum: 5/1/2022

If you are sending Prenotification letters please provide the following:

- 1. Formulary in place as of effective date of the letter: NPF

Sponsor hereby directs Express Scripts to implement the selected programs on the attached Clinical Programs schedule as of the Effective Date. Sponsor agrees to pay the applicable fees in accordance with the payment provisions of the PBM Agreement. Upon execution by Sponsor, this Addendum shall replace and supersede any previously executed Clinical Programs schedule Addendum as it pertains to the programs contained herein and shall become part of and incorporated into the PBM Agreement between Sponsor and Express Scripts identified above as of the Effective Date.

Sponsor acknowledges that due to variations in benefit plan design and product utilization, the Preferred Specialty Management ("PSM") program generated savings will vary at the individual claim level. In limited cases, based on how a drug is prescribed, a Prescription Drug Claim subject to the PSM program could result in a higher cost to Sponsor. However, in the aggregate across all Prescription Drug Claims subject to the PSM program, the PSM program is estimated to produce an overall net client savings for Sponsor.

Sponsor acknowledges and agrees that any provisions in Sponsor's Pharmacy Benefit Management Agreement with ESI relating to drug interchange that may be interpreted to require that every Prescription Drug Claim resulting from a drug interchange must result in savings to the Sponsor will not apply to each Prescription Drug Claim subject to the PSM program.

By signing below, Sponsor agrees to the prices and terms set forth in this PBM Agreement Service Addendum.

If this Form was communicated to Sponsor as an attachment to an electronic communication (i.e., email), then any response to such email from Sponsor indicating Sponsor's approval shall constitute Sponsor's electronic signature to implement the changes set forth.

AUTHORIZED SIGNATURE:

TITLE:

(Signatory must have authority to legally bind Sponsor)

Date Signed



Clinical Programs - SafeGuardRx

Express Scripts (ESI) offers a comprehensive suite of trend and integrated health management programs. This offering may change or be discontinued from time to time as we update our offering to meet the needs of the marketplace. List of drugs subject to change at the discretion of ESI.

SAFEGUARD RX - Programs									
Hepatitis Cure Value	Fee - PMPM	Guarantee	In Place	Add	Remove	Continuation of Therapy	PreNotify	Cov Review	
Program Requirements: Hepatitis Cure Value Exclusive Accredo, no courtesy fills for Harvoni & Eplusa NPF and/or Utilization Management on Hep C Products PA criteria must not contain Metavir score requirements Express Scripts standard clinical criteria Express Scripts standard clinical rules Automatic updates (if applicable)				X					ESI managed
NPF (No clinical enrollment)	\$0.00	Year End Reconciliation		X					ESI managed
Cardiovascular Care Value	Fee - PMPM	Guarantee	In Place	Add	Remove	Continuation of Therapy	PreNotify	Cov Review	
Program Requirements: Cardiovascular Care Value Eliquis and Xarelto available at open network including Retail pharmacy and Home Delivery depending on plan design Comprehensive prior authorization for PCSK9s Express Scripts Therapeutic Resource Center (TRC) outreach Express Scripts standard clinical criteria Express Scripts managed coverage reviews Express Scripts standard clinical rules (includes PA & DQM) Automatic updates (if applicable)				X					ESI managed
NPF / Basic / High Performance	\$0.00	Year End Reconciliation • PCSK9 inhibitors \$65 PMPY cost cap		X					ESI managed
Oncology Care Value	Fee - PMPM	Guarantee	In Place	Add	Remove	Continuation of Therapy	PreNotify	Cov Review	
Option 1: Program Requirements: Oncology Care Value Exclusive Accredo, no courtesy fills for all oncology medications Oncology drug preference by indication Express Scripts standard criteria Express Scripts managed coverage reviews Express Scripts standard clinical rules (includes PA) Automatic updates Continuation of Therapy for Kisqali in place via criteria				X		X			ESI managed
Commercial	\$0.00	•Pharmacogenomic Testing •Year End Reconciliation • Early discontinuation reimbursement		X		X			ESI managed
Inflammatory Conditions Care Value	Fee - PMPM	Guarantee	In Place	Add	Remove	Continuation of Therapy	PreNotify	Cov Review	
Option 1: Program Requirements: Inflammatory Conditions Care Value Exclusive Accredo, no courtesy fills for all inflammatory conditions medications Inflammatory condition drug preference by indication Express Scripts standard criteria Express Scripts managed coverage reviews Express Scripts standard clinical rules Automatic updates Continuation of Therapy in place via automation via criteria. (No Continuation of Therapy will be available for Cosentyx post 1/1/2021)				X		X			ESI managed
NPF / Basic	\$0.00			X		X			ESI managed
Market Events Protection Program	Fee - PMPM	Guarantee	In Place	Add	Remove	Continuation of Therapy	PreNotify	Cov Review	
Program Requirements: Market Events Any of the following actions may be taken in response to a market event: Block brand Block generic Prefer a clinically equivalent alternative Implement a prior authorization Dosage form changes				X					ESI managed
Commercial	\$0.00			X					ESI managed
Multiple Sclerosis Care Value	Fee - PMPM	Guarantee	In Place	Add	Remove	Continuation of Therapy	PreNotify	Cov Review	
Option 1: Program Requirements: Multiple Sclerosis Care Value Exclusive Accredo, no courtesy fills for all MS medications NPF and/or Utilization Management on MS Products Express Scripts standard criteria Express Scripts managed coverage reviews Express Scripts standard clinical rules Automatic updates Continuation of Therapy in place via criteria				X					ESI managed

Cardiovascular Care Value Notes:

- 1) Sponsor must utilize the Express Scripts CCV Prior Authorization criteria for PCSK9s.
- 2) Express Scripts must manage Sponsor's prior authorization process.
- 3) Claims for which Sponsor overrides ESI's PA criteria will not be eligible to be included in the program.
- 4) The Program does not apply to patients receiving therapy for off-label indications.
- 5) Sponsor agrees that Express Scripts Therapeutic Resource Center (TRC) clinicians may contact Sponsor's members and/or physicians to discuss the CCV Program.
- 6) Sponsor agrees that, if available, Express Scripts may use information included in medical claims data (alone or together with data from other sources) for the purpose of performing outcomes and/or opportunity analyses, for health, safety and wellness programs, pharmacy benefit plan administration, practice of pharmacy and other analytics.

Cost Cap:

- 1) ESI will provide Sponsor with a per member per year Cost Cap on PCSK9s. ESI will provide Sponsor with a credit, dollar for dollar, to the extent that Sponsor's actual preferred PCSK9 product spend of preferred products as part of the Cardiovascular Care Value Program (net of Rebates and Manufacturer Administrative Fees) exceeds the PMPY cap. ESI will determine if the PMPY cap is exceeded by comparing the cap to the result of the following equation: Sponsor's actual ingredient cost billed for preferred products for the calendar year, less any Rebates and Manufacturer Administrative Fees paid divided by the average enrollment in Sponsor's Plans during the calendar year.
- 2) Only PCSK9 utilization while Sponsor is enrolled in the Cardiovascular Care Value Program will count towards the PMPY cost cap. Only utilization while the patient is covered by Sponsor will apply.
- 3) The PMPY Cap may be adjusted if there are significant changes to the FDA approved labels for preferred PCSK9 products as part of the Cardiovascular care value program. ESI may adjust the PMPY cap if outcomes trials are released that materially change prescriber behavior. ESI may also adjust the cap if the number of Sponsor's members enrolled in the program drops below 1,000.
- 4) The PMPY cost cap is only applicable to preferred PCSK9 product claims as part of the Cardiovascular Care Value Program and does not include the cost of any other therapies used by the patient, including statin therapy.
- 5) The total value to be paid to Sponsor under PCSK9 Cost Cap will not exceed 70% of AWP of the products dispensed to Sponsor's members.
- 6) The PMPY PCSK9 Cost Cap will apply only to claims dispensed after all prior authorization criteria are implemented for Sponsor's plans.
- 7) Sponsor may be eligible for additional discounts which will be paid out on an annual basis for Preferred Cardiovascular Care Value Products. The list of Preferred Cardiovascular Care Value Products and their associated credit value, will be available to Sponsor upon request.
- 8) ESI reserves the right to retain an administrative fee, not to exceed 2.75% of wholesale acquisition cost of the pharmaceutical product from the payments which are paid to Sponsor in exchange for ESI's services rendered under the programs.

COMMERCIAL: Click below link to view the full terms and conditions of the programs. If you have difficulty accessing the terms and conditions or require a printed version, please reach out to your account team contact.

COMMERCIAL CCV LINK

<https://www.express-scripts.com/tc/TC-CCV-CD-NR.pdf>

Oncology Care Value Notes:

1. Sponsor's pharmacy network must be set to exclusive Accredo for all oncology drugs, when Accredo has access to the oncology drug, with no courtesy fills allowed at any other pharmacy.
2. Sponsors must accept applicable drug preference requirements at the indication level and formulary status updates to qualify for applicable discounts at Accredo.
3. Sponsors must accept automatic updates and/or enhancements to the program to continue to qualify for applicable discounts at Accredo.
4. Express Scripts must manage Sponsor's PA process.
5. Claims for which Sponsor overrides the applicable PA criteria will not be eligible for, or included in, any portion of the program.
6. If Sponsor participates in the program, Sponsor will be eligible for additional discounts or credits, which will be paid out on an annual basis for all specified oncology products dispensed at Accredo. The list of products, and their associated discount rates or credit value, will be provided to Sponsor upon request and will be reflected in the invoices sent to Sponsor. The list of specified products (and their associated discounts) may be updated by ESI from time to time upon notice to Sponsor.
7. As part of the Oncology Care Value Program, Express Scripts will provide Sponsor with participation in Express Scripts' Pharmacogenomic Testing program ("Testing Services"). Testing Services are optional for patients and are ordered at the discretion of the patient's physician. Results are used by the patient's physician to assess a patient's response to therapy. Express Scripts may receive additional discounts from pharmaceutical manufacturers based on Sponsor's eligible utilization of Oncology Products by eligible OCV patients in connection with the OCV Program (the "OCV Pharma Value"). All OCV Pharma Value will be distributed to Sponsor as part of the OCV Program; however Sponsor agrees to allow Express Scripts to deduct an amount equal to the fair market value that Sponsor would have been charged for the Testing Services from the OCV Pharma Value. Participation in the Pharmacogenomic Testing program is not conditioned upon Sponsor making any benefit design changes.

COMMERCIAL: Click below link (<https://www.express-scripts.com/art/pdf/TC-OCV.pdf>) to view the full terms and conditions of the programs. If you have difficulty accessing the terms and conditions or require a printed version, please reach out to your account team contact.

[OCV Commercial Division Terms and Conditions](#)

Inflammatory Conditions Care Value Notes:

- 1) Sponsor's benefit design must be set to exclusive Accredo for inflammatory conditions' drugs with no courtesy fills allowed at any other pharmacy.
 - 2) Sponsor must be enrolled in Express Script's National Preferred Formulary, or a clone thereof, or utilization management programs that drives preference by indication for the applicable Inflammatory Products.
 - 3) Claims for which Sponsor overrides the applicable PA criteria will be excluded from all components of the program
- Early Discontinuation:
- 1) Early discontinuation only applies in situations when a member has their initial and subsequent fills at Accredo
 - 2) Sponsor will only be reimbursed up to one time per patient for each unique preferred inflammatory condition drug
 - 3) To be eligible for the ICCV Discontinuation Credit, the ICCV Patient must start (receive their first fill) at Accredo and remain at Accredo through discontinuation of therapy. In addition, the ICCV Patient must have been continuously eligible in the prior 270 days and remained covered by Sponsor for the duration of the credit period. (i.e., must remain benefit eligible) and Sponsor must be able to provide 270 days of claims data evidencing that the patient has not previously filled an Inflammatory Product.

General Terms:

- 1) ESI reserves the right to retain an administrative fee, not to exceed 2.75% of wholesale acquisition cost of the pharmaceutical product from the payments which are paid to Sponsor in exchange for ESI's services rendered under the programs.

COMMERCIAL: Click below link (<https://www.express-scripts.com/tc/TC-ICCV-CD.pdf>) to view the full terms and conditions of the programs. If you have difficulty accessing the terms and conditions or require a printed version, please reach out to your account team contact.

[ICCV Commercial Division Terms and Conditions](#)

Market Event Protection Program Notes:

- 1) Sponsor acknowledges and agrees that for certain actions to be taken when preferring a specific medication, Sponsor must have dispense as written ("DAW") code(s) 5 and/or 9 enabled for adjudication to prevent potential member disruption. By enrolling, Sponsor agrees to enable DAW 5 and/or 9, if necessary.
- 2) ESI will provide Sponsor advance notice of any action taken under the Program. ESI will provide Sponsor's members advance notice of any action taken under the Program if such action has a direct member impact that will require a member to take action (e.g. if a new prescription may be required).
- 3) Sponsor may disenroll from the Program at any time, provided that ESI is given 30 days advance written notice. If Sponsor disenrolls from the program, any authorized action previously taken under the Program during Sponsor's enrollment will no longer apply and Sponsor will be reverted back to its state prior to enrollment in the Program.
- 4) Claims impacted by the Program will be adjudicated and reconciled in accordance with the pricing set forth in the PBM Agreement. Nothing herein changes the pricing guarantees under the PBM agreement.
- 5) The current list of market events eligible for the Program and the specific actions that Sponsor is authorizing ESI to take are set forth in the table included in the full terms and conditions of the program. Market events will be reviewed on a book of business basis.

Click below link (<https://www.express-scripts.com/tc/TC-ME-CD.pdf>) to view the full terms and conditions of the programs. If you have difficulty accessing the terms and conditions or require a printed version, please reach out to your account team contact.

Multiple Sclerosis Care Value Notes:

- 1) Sponsor's benefit design must be set to exclusive Accredo for multiple sclerosis drugs with no courtesy fills allowed at any other pharmacy.
- 2) Sponsor must be enrolled in Express Script's National Preferred Formulary, or a clone thereof, and/or utilization management programs that drives preference for the applicable Multiple Sclerosis Products.
- 3) Claims for which Sponsor overrides the applicable PA criteria will be excluded from all components of the program Early Discontinuation:
 - 1) Early discontinuation only applies in situations when a member has their initial and subsequent fills at Accredo
 - 2) Sponsor will only be reimbursed up to one time per patient for each unique preferred multiple sclerosis drug
 - 3) To be eligible for the MSCV Discontinuation Credit, the MSCV Patient must start (receive their first fill) at Accredo and remain at Accredo through discontinuation of therapy. In addition, the MSCV Patient must have been continuously eligible in the prior 270 days and remained covered by Sponsor for the duration of the credit period. (i.e., must remain benefit eligible) and Sponsor must be able to provide 270 days of claims data evidencing that the patient has not previously filled a Multiple Sclerosis Product.

General Terms:

- 1) ESI reserves the right to retain an administrative fee, not to exceed 2.75% of wholesale acquisition cost of the pharmaceutical product from the payments which are paid to Sponsor in exchange for ESI's services rendered under the programs.

Click below link (<https://www.express-scripts.com/tc/TC-MSCV-CD.pdf>) to view the full terms and conditions of the programs. If you have difficulty accessing the terms and conditions or require a printed version, please reach out to your account team contact.

Rare Conditions Care Value Notes:

- 1) Sponsor's benefit design must be set to exclusive Accredo for rare condition drugs with no courtesy fills allowed at any other pharmacy.
- 2) Sponsor must be enrolled in Express Script's National Preferred Formulary, or a clone thereof, and/or utilization management programs that drives preference for the applicable Rare Condition Products.
- 3) Claims for which Sponsor overrides the applicable PA criteria will be excluded from all components of the program
- 4) If Sponsor participates in the program, Sponsor will be eligible for additional savings which will be paid out on an annual basis for all Preferred Rare Conditions Products dispensed at Accredo. The list of Preferred Rare Conditions Products and their associated credit value, will be provided to Sponsor upon request.
- 5) For select medications, a client will be eligible for capping the cost of treatment for patients on the therapy during the calendar year.
- 6) Only utilization while Sponsor is enrolled in the Rare Conditions Care Value Program will count towards the cost cap. Only utilization while the patient is covered by Sponsor will apply.

General Terms

- 1) ESI reserves the right to retain an administrative fee, not to exceed 2.75% of wholesale acquisition cost of the pharmaceutical product from the payments which are paid by Sponsor in exchange for ESI's services rendered under the programs.

Click below link to view the full terms and conditions of the programs. If you have difficulty accessing the terms and conditions or require a printed version, please reach out to your account team contact.

Neurological Care Value Notes:

- 1) Sponsor must be enrolled in Express Script's National Preferred Formulary, or a clone thereof, and/or utilization management programs that drives preference for the applicable Neurological Care Value Products.
- 2) Claims for which Sponsor overrides the applicable PA criteria will be excluded from all components of the program
- 3) If Sponsor participates in the program, Sponsor will be eligible for additional savings which will be paid out on an annual basis for all Preferred Preventative Neurological Products and all Preferred Acute Neurological Products dispensed to Members. The list of Preferred Neurological Products and their associated credit value, will be provided to Sponsor upon request.
- 4) Discontinuation Credit for members who discontinue therapy early may apply. To be eligible for the NCV Discontinuation Credit, the member must have been continuously covered by Sponsor's pharmacy benefit plan under Express Scripts in the prior 130 days leading to the first fill and remained covered by Sponsor for the duration of the credit period (i.e., must remain benefit eligible)

General Terms

- 1) ESI reserves the right to retain an administrative fee, not to exceed 2.75% of wholesale acquisition cost of the pharmaceutical product from the payments which are paid by Sponsor in exchange for ESI's services rendered under the programs.

Click below link to view the full terms and conditions of the programs. If you have difficulty accessing the terms and conditions or require a printed version, please reach out to your account team contact.

HIV Care Value Notes:

- HIV Products must not be restricted or disadvantaged with respect to formulary status or step therapy. Sponsor's prior authorization or other utilization management imposed on HIV Preferred Products shall be no more restrictive than the FDA-approved label for such HIV Preferred Product. If at any time Sponsor does not meet these requirements, Sponsor is not eligible for participation in the HIVCV Program and notwithstanding anything herein to the contrary, will be disenrolled as soon as reasonably practicable.

General Terms

- As part of the HIV Care Value Program, Express Scripts will provide Sponsor with participation in clinical programs, including but not limited to, patient engagement tools and/or adherence outreach programs (the "Programs"). Express Scripts may receive additional discounts from pharmaceutical manufacturers in connection with the HIVCV Program (the "HIVCV Pharma Value"). As consideration for the administrative services rendered under the HIVCV Program (including the Programs), Express Scripts is entitled to an administrative fee paid by Sponsor not to exceed 2.75% of the Wholesale Acquisition Cost of the HIV Products covered under the HIVCV Program (the "HIVCV Admin Fee"). For convenience and ease of administration, Express Scripts may retain the HIVCV Admin Fee out of the HIVCV Pharma Value. If any additional HIVCV Pharma Value is remaining after subtraction of the HIVCV Admin Fee it will be distributed to Sponsor as part of the HIVCV Program.
- Starting January 1, 2021, Express Scripts will provide Sponsor's Members with the opportunity to utilize a patient engagement tool. The patient engagement tool is a pill bottle cap that will leverage digital capabilities to help members take medications on time with support through reminders and alerts.
- Express Scripts reserves the right to terminate or modify the program at any time.
- Medicare, Medicaid, and other government health care program claims will be excluded from the program.

Clinical Programs

Express Scripts (ESI) offers a comprehensive suite of trend and integrated health management programs.

This offering may change or be discontinued from time to time as we update our offering to meet the needs of the marketplace.

List of drugs subject to change at the discretion of ESI

Additional fees apply for custom rules

Prior Authorization, Drug Quantity Management and some Step Therapy rules (with exceptions) do not have logic to add Continuation of Therapy (COT) and can invalidate savings guarantees.

Utilization Management Packages	Fee - PMPM	In Place	Add	Remove	Continuation of Therapy (CoT)	PreNotify	Cov Review
Advantage Plus UM Package Includes all items in the Limited UM Package: Limited PA Proactive PA Limited DQM Limited Step Therapy Plus all items in the Advantage UM Package: Advantage PA Nonessential Therapy PA Advantage DQM Preferred Specialty Management Advantage Step Therapy Plus Advantage Plus PA Pharmacogenomic PA Oncology Package Advantage Plus DQM Advantage Plus Step Therapy	\$1.20 PMPM		X			X	ESI Managed
Prior Authorization Intervene to support appropriate use at the point of service through pre-established clinical criteria Automatic Updates to the below programs apply.	Fee - PMPM	In Place	Add	Remove	Continuation of Therapy (CoT)	PreNotify	Cov Review
Limited PA List	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Limited PA List			X			X	ESI Managed
Adakveo			X			X	ESI Managed
Adempas			X			X	ESI Managed
Alpha1 Proteinase Inhibitors (Aralast NP/Glassia/Prolastin/Prolastin C/Zemaira)			X			X	ESI Managed
Aranesp			X			X	ESI Managed
Arikayce			X			X	ESI Managed
Avonex			X			X	ESI Managed
Betaseron, Extavia			X			X	ESI Managed
Bronchitol			X			X	ESI Managed
Cholbam			X			X	ESI Managed
Copaxone			X			X	ESI Managed
Cystic Fibrosis Inhaled Antibiotics (Tobi, Tobi Podhaler, Bethkis, Kitabis)			X			X	ESI Managed
Daliresp			X			X	ESI Managed
Daraprim			X			X	ESI Managed
Egrifta			X			X	ESI Managed
Emflaza			X			X	ESI Managed
Endari			X			X	ESI Managed
Epogen, Procrit and biosimilars			X			X	ESI Managed
Esbriet			X			X	ESI Managed

Firdapse, Ruzurgi			X			X	ESI Managed
Flolan, Remodulin, Veletri			X			X	ESI Managed
Gaucher's Disease (Cerdelga, Cerezyme, Elelyso, Vpriv, Zavesca)			X			X	ESI Managed
Growth Hormones (Genotropin, Humatrope, Norditropin Novo Nordisk, Nutropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Tev-Tropin, Zorbtive)			X			X	ESI Managed
Hetlioz			X			X	ESI Managed
Hyaluronic Acid Derivatives (Euflexxa, Gel-One, Hyalgan, Monovisc, Orthovisc, Supartz, Synvisc, Synvisc-One)			X			X	ESI Managed
Increlex			X			X	ESI Managed
Iron Deficiency Anemia - Feraheme, Ferrlecit, INFeD, Injectafer, Monoferic, Venofer			X			X	ESI Managed
Ivermectin			X			X	ESI Managed
Kerendia			X			X	ESI Managed
Kesimpta			X			X	ESI Managed
Lemtrada			X			X	ESI Managed
Letairis, Tracleer, Opsumit			X			X	ESI Managed
Makena			X			X	ESI Managed
Mircera			X			X	ESI Managed
MS Oral (Ampyra, Ozanimod, Mayzent, Mavenclad, diroximel fumarate, Gilenya, Aubagio, Tecfidera, Vumerity, Ponvory)			X			X	ESI Managed
Myalept			X			X	ESI Managed
Northera			X			X	ESI Managed
Ocrevus			X			X	ESI Managed
Ofev			X			X	ESI Managed
Oral Anti-fungals (Cresemba, Noxafil, Vfend (Oral))			X			X	ESI Managed
Orenitram			X			X	ESI Managed
Oxbryta			X			X	ESI Managed
PDE-5 inhibitors for PAH (Adcirca, Revatio) (retiring 1/1/2022)			X			X	ESI Managed
Plegridy			X			X	ESI Managed
Pretomanid			X			X	ESI Managed
Rebif			X			X	ESI Managed
Reblozyl			X			X	ESI Managed
Riluzole Products (Rilutek, Tiglutik)			X			X	ESI Managed
Sirturo			X			X	ESI Managed
Tysabri			X			X	ESI Managed
Tyvaso, Ventavis			X			X	ESI Managed
Uptravi			X			X	ESI Managed
Veklury			X			X	ESI Managed
Veregen			X			X	ESI Managed
Xeomin			X			X	ESI Managed
Advantage PA List		In Place	Add	Remove	CoT	PreNotify	Cov Review

<u>Advantage PA List</u>			X			X	ESI Managed
Actemra			X			X	ESI Managed
Aimovig			X			X	ESI Managed
Ajovy			X			X	ESI Managed
Benlysta SC, IV			X			X	ESI Managed
Cimzia			X			X	ESI Managed
Cinqair			X			X	ESI Managed
Cosentyx			X			X	ESI Managed
Crysvita			X			X	ESI Managed
Dupixent			X			X	ESI Managed
Emgality			X			X	ESI Managed
Enbrel			X			X	ESI Managed
Enspryng			X			X	ESI Managed
Entyvio			X			X	ESI Managed
Evenity			X			X	ESI Managed
Evkeeza			X			X	ESI Managed
Fasenra			X			X	ESI Managed
Forteo			X			X	ESI Managed
Granix			X			X	ESI Managed
Grastek, Oralair			X			X	ESI Managed
Hemlibra			X			X	ESI Managed
HemoPhilia Factor VII (7) (Novosven RT, Feiba, Sevenfact)			X			X	ESI Managed
Hemophilia Factor VIII (8) Products			X			X	ESI Managed
Hemophilia Factor IX (9) Products			X			X	ESI Managed
HemoPhilia Factor X (10) (Coagadex)			X			X	ESI Managed
HemoPhilia Factor XIII (13) (Corifact, Tretten)			X			X	ESI Managed
HemoPhilia Von Willebrand (Vovendi)			X			X	ESI Managed
Humira			X			X	ESI Managed
Ilumya			X			X	ESI Managed
Kevzara			X			X	ESI Managed
Kineret			X			X	ESI Managed
Lidocaine Patch			X			X	ESI Managed
Lovaza, Vascepa			X			X	ESI Managed
Lupkynis			X			X	ESI Managed
Natpara			X			X	ESI Managed
Neulasta and biosimilars			X			X	ESI Managed
Neupogen			X			X	ESI Managed
Nexletol			X			X	ESI Managed
Nexlizet			X			X	ESI Managed
Nocurna			X			X	ESI Managed

Nucala			X			X	ESI Managed
Nurtec			X			X	ESI Managed
Odactra			X			X	ESI Managed
Olumiant			X			X	ESI Managed
Orencia			X			X	ESI Managed
Otezla			X			X	ESI Managed
Palforzia			X			X	ESI Managed
Ragwitek			X			X	ESI Managed
Remicade and biosimilars			X			X	ESI Managed
Reyvow			X			X	ESI Managed
Rinvoq			X			X	ESI Managed
Rituxan, Ruxience, Truxima			X			X	ESI Managed
Siliq			X			X	ESI Managed
Simponi			X			X	ESI Managed
Skyrizi			X			X	ESI Managed
Solaraze			X			X	ESI Managed
Soliris			X			X	ESI Managed
Stelara			X			X	ESI Managed
Taltz			X			X	ESI Managed
Tremfya			X			X	ESI Managed
Tymlos			X			X	ESI Managed
Ubrovly			X			X	ESI Managed
Ultomiris			X			X	ESI Managed
Uplizna			X			X	ESI Managed
Vyepti			X			X	ESI Managed
Xeljanz			X			X	ESI Managed
Xolair			X			X	ESI Managed
Zarxio, Nivestym			X			X	ESI Managed
Zovirax			X			X	ESI Managed
Advantage Plus PA List		In Place	Add	Remove	CoT	PreNotify	ESI Managed
Advantage Plus PA List			X			X	ESI Managed
Aduhelm			X			X	ESI Managed
Banzel			X			X	ESI Managed
Chemet			X			X	ESI Managed
Combination Beta Agonist/ICS (Advair Diskus, Advair HFA, Breo Ellipta, Dulera, Symbicort)			X			X	ESI Managed
Corlanor			X			X	ESI Managed
Diacomit			X			X	ESI Managed
Eliquis			X			X	ESI Managed
Epidiolex			X			X	ESI Managed

Fentanyl Transmucosal Drugs (Abstral, Actiq, Fentora, Onsolis, Subsys, Lazanda)			X			X	ESI Managed
Fintepla			X			X	ESI Managed
Inbrija			X			X	ESI Managed
Iron Chelators (Oral)			X			X	ESI Managed
Kynmobi			X			X	ESI Managed
Long Acting Opioids - Oral (CoT Required)			X			X	ESI Managed
Lucemyra			X			X	ESI Managed
Myfembree			X			X	ESI Managed
Nayzilam			X			X	ESI Managed
Nouriaz			X			X	ESI Managed
Nuplazid			X			X	ESI Managed
Ongentys			X			X	ESI Managed
Oriahnn			X			X	ESI Managed
Orlissa			X			X	ESI Managed
Pradaxa			X			X	ESI Managed
Savaysa			X			X	ESI Managed
Somatostatin Analogs PA (CoT not available)			X			X	ESI Managed
Spravato			X			X	ESI Managed
Sympazan, Onfi			X			X	ESI Managed
Syprine			X			X	ESI Managed
Valtoco			X			X	ESI Managed
Vigabatrin (Sabril)			X			X	ESI Managed
Xarelto			X			X	ESI Managed
Zontivity			X			X	ESI Managed
Zulresso			X			X	ESI Managed
Nonessential Therapy PA List	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Nonessential Therapy PA List Full List: Please Note: Current drug exclusions will stay excluded unless requested under separate Service Request.			X			X	ESI Managed
Addyi, Vyleesi			X			X	ESI Managed
Aklief			X			X	ESI Managed
Alprostadil Products (Edex, Caverject, Caverject Impulse, MUSE)			X			X	ESI Managed
Botox			X			X	ESI Managed
Cialis			X			X	ESI Managed
Dysport			X			X	ESI Managed
Eysuvis			X			X	ESI Managed
GLP-1 Agonists (Byetta, Bydureon, Trulicity, Victoza) Incretin Mimetics			X			X	ESI Managed
Injectable Testosterone (Aveed®, Depo® - Testosterone [testosterone cypionate injection, generics], Delatestryl®, Xyosted® [testosterone enanthate injection, generics], Testopel® [testosterone pellet])			X			X	ESI Managed
Lacrisert			X			X	ESI Managed
Levitra/Staxyn			X			X	ESI Managed

Mirvaso, Rhofade cream			X			X	ESI Managed
Myobloc			X			X	ESI Managed
Ophthalmic Prostaglandin (Durysta, Lumigan, Xalatan[Generics], Travatan, Travatan Z, Zioptan)			X			X	ESI Managed
Qbrexza			X			X	ESI Managed
Restasis, Cequa			X			X	ESI Managed
Stendra			X			X	ESI Managed
Symlin			X			X	ESI Managed
Topical Tazarotene Products (Tazorac® 0.05% and 0.1% cream, gel - Allergan; Fabior 0.1% foam - Stiefel)			X			X	ESI Managed
Topical Testosterone (Androderm, AndroGel, Axiron, Fortesta, Natesto, Striant, Testim, Vogelxo)			X			X	ESI Managed
Topical Tretinoin-Indication age limit is MANDATORY. Age recommendation: Covered through age 30 and PA will apply for age 31 and older. PA Age Selection = 29 and older (Retin-A®, Retin-A® Micro® - Ortho; Avita® - Bertek Pharmaceuticals; Tretin-X™ - Triax; Atralin™ gel - Coria; other generic topical tretinoin products - various manufacturers) and Clindamycin Phosphate 1.2% and Tretinoin 0.025% gel(Ziana(R) - Medicis; Veltin(TM) - Stiefel)			X			X	ESI Managed
Upneeq			X			X	ESI Managed
Viagra			X			X	ESI Managed
Weight Loss Drugs (Adipex (phentermine), Bontril [phendimetrazine], Contrave (bupropion; naltrexone), Didrex [benzphetamine], Sanorex [mazindol], Suprenza [phentermine], Tenuate [diethylpropion], Xenical [orlistat], Belviq, Qsymia,Saxenda), Wegovy			X			X	ESI Managed
Winlevi			X			X	ESI Managed
Xiaflex			X			X	ESI Managed
Xiidra			X			X	ESI Managed
Pharmacogenomic PA List	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Pharmacogenomics PA List			X			X	ESI Managed
Adcetris (also Included in Oncology Package)			X			X	ESI Managed
Afinitor (also Included in Oncology Package)			X			X	ESI Managed
Alecensa (also Included in Oncology Package)			X			X	ESI Managed
Alunbrig (also Included in Oncology Package)			X			X	ESI Managed
Ayvakit (also Included in Oncology Package)			X			X	ESI Managed
Balversa (also Included in Oncology Package)			X			X	ESI Managed
Bosulif (also Included in Oncology Package)			X			X	ESI Managed
Braftovi (also Included in Oncology Package)			X			X	ESI Managed
Cabometyx (also Included in Oncology Package)			X			X	ESI Managed
Caprelsa (also Included in Oncology Package)			X			X	ESI Managed
Cometriq (also Included in Oncology Package)			X			X	ESI Managed
Cotellic (also Included in Oncology Package)			X			X	ESI Managed
Dojolvi			X			X	ESI Managed
Duchenne Muscular Dystrophy (i.e., Amondys 45, Exondys 51, Vyondys-53, Viltepso)			X			X	ESI Managed
Enhertu (also included in Oncology Package)			X			X	ESI Managed
Epclusa			X			X	ESI Managed
Erbitux/Vectibix			X			X	ESI Managed
Evrysdi			X			X	ESI Managed
Folotyn (also included in Oncology Package)			X			X	ESI Managed

Galafold			X			X	ESI Managed
Gamifant			X			X	ESI Managed
Gilotrif (also Included in Oncology Package)			X			X	ESI Managed
Harvoni			X			X	ESI Managed
Ibrance (also Included in Oncology Package)			X			X	ESI Managed
Iclusig (also Included in Oncology Package)			X			X	ESI Managed
Idhifa (also Included in Oncology Package)			X			X	ESI Managed
Imcivree			X			X	ESI Managed
Iressa (also Included in Oncology Package)			X			X	ESI Managed
Kadcyla (also Included in Oncology Package)			X			X	ESI Managed
Kalydeco			X			X	ESI Managed
Keveyis			X			X	ESI Managed
Keytruda (also included in Oncology Package)			X			X	ESI Managed
Kisqali (also Included in Oncology Package)			X			X	ESI Managed
Lonsurf (also Included in Oncology Package)			X			X	ESI Managed
Lorbrena (also Included in Oncology Package)			X			X	ESI Managed
Luxturna			X			X	ESI Managed
Lynparza (also Included in Oncology Package)			X			X	ESI Managed
Mavyret			X			X	ESI Managed
Mekinist (also Included in Oncology Package)			X			X	ESI Managed
Mektovi (also Included in Oncology Package)			X			X	ESI Managed
Mylotarg (also Included in Oncology Package)			X			X	ESI Managed
Nerlynx (also Included in Oncology Package)			X			X	ESI Managed
Hereditary Tyrosinemia (Nityr, nitisinone, Orfadin)			X			X	ESI Managed
Onpattro			X			X	ESI Managed
Opdivo (also included in Oncology Package)			X			X	ESI Managed
Orkambi			X			X	ESI Managed
Oxlumo			X			X	ESI Managed
Pegasys,PegIntron			X			X	ESI Managed
Pemazyre			X			X	ESI Managed
Perjeta			X			X	ESI Managed
Romidepsin (also included in Oncology Package)			X			X	ESI Managed
Rozlytrek (also included in Oncology Package)			X			X	ESI Managed
Rubraca (also included in Oncology Package)			X			X	ESI Managed
Rydapt (also Included in Oncology Package)			X			X	ESI Managed
Sovaldi			X			X	ESI Managed
Spinraza			X			X	ESI Managed
Sprycel (also Included in Oncology Package)			X			X	ESI Managed
Stivarga (also Included in Oncology Package)			X			X	ESI Managed
Strensiq			X			X	ESI Managed
Symdeko			X			X	ESI Managed
Synribo (also Included in Oncology Package)			X			X	ESI Managed
Tabrecta (also Included in Oncology Package)			X			X	ESI Managed
Tafinlar (also Included in Oncology Package)			X			X	ESI Managed
Tagrisso (also Included in Oncology Package)			X			X	ESI Managed
Talzenna (also Included in Oncology Package)			X			X	ESI Managed
Tarceva (also Included in Oncology Package)			X			X	ESI Managed

Tasigna (also Included in Oncology Package)			X			X	ESI Managed
Tegsedi			X			X	ESI Managed
Tibsovo (also Included in Oncology Package)			X			X	ESI Managed
Trastuzumab			X			X	ESI Managed
Trikafta			X			X	ESI Managed
Tykerb (also Included in Oncology Package)			X			X	ESI Managed
Verzenio (also Included in Oncology Package)			X			X	ESI Managed
Viekira			X			X	ESI Managed
Vitakvi (also Included in Oncology Package)			X			X	ESI Managed
Vizimpro (also Included in Oncology Package)			X			X	ESI Managed
Vosevi			X			X	ESI Managed
Vyndaqel, Vyndamax			X			X	ESI Managed
Xalkori (also Included in Oncology Package)			X			X	ESI Managed
Xospata (also Included in Oncology Package)			X			X	ESI Managed
Yervoy (also Included in Oncology Package)			X			X	ESI Managed
Zelboraf (also Included in Oncology Package)			X			X	ESI Managed
Zepatier			X			X	ESI Managed
Zokinvy			X			X	ESI Managed
Zolgensma			X			X	ESI Managed
Zykadia (also Included in Oncology Package)			X			X	ESI Managed
Adjunctive Specialty PA List	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Adjunctive Specialty PA List	\$0.05		X			X	ESI Managed
Cabenuva			X			X	ESI Managed
GnRH implants (Supprelin LA, Vantas, and Zoladex)			X			X	ESI Managed
H.P. Acthar Gel			X			X	ESI Managed
IVIIG (Asceniv, Atgam, Bivigam, Carimune, Cytogam, Flebogamma DIF, Gammagard, Gammagard S/D, Octagam, Privigen, Gammaplex, Gamunex, Gammaked)			X			X	ESI Managed
Leuprolide Injectable Long Acting- GnRH Agonists (Fensolvi, Lupron Depot®, Lupron Depot-Ped®, Eligard®, Lupaneta®, Triptodur)			X			X	ESI Managed
Prolia			X			X	ESI Managed
Reclast/Boniva			X			X	ESI Managed
Revcovi, Adagen			X			X	ESI Managed
Ribavirin (Copegus, Rebetol, Ribasphere)			X			X	ESI Managed
Rukobia			X			X	ESI Managed
SCIG (Gammagard Liquid, Gammaked, Gamunex-C, Hizentra, Hyqvia)			X			X	ESI Managed
Synagis			X			X	ESI Managed
Synarel			X			X	ESI Managed
Trogarzo			X			X	ESI Managed
Oncology Package PA - Full Package Only	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Abecma							
Afinitor							
Alecensa							
Aliqopa							
Alunbrig							
Arzerra							
Arsenic Trioxide (Trisenox)							
Asparlas							
Avastin							
Ayvakit							
Azedra							
Balversa							

Bavencio
Beleodaq
Bendamustine products (Bendeka, Treanda, Belrapzo)
Besponsa
Blenrep
Blincyto
Bosulif
Braftovi
Breyanzi
Brukinsa
Cabometyx
Calquence
Caprelsa
Carmustine
Cometriq
Copiktra
Cotellic
Cytamza
Dacogen
Danyelza
Darzalex
Daurismo
Elzonris
Empliciti
Enhertu
Erivedge
Erleada
Erwinaze
Farydak
Faslodex
Folotyn
Fotvida
Gavreto
Gazyva
Gilotrif
Gleevec
GNRH for Prostate Cancer Injectables
Halaven
Hycamtin
Ibrance
Iclusig
Idhifa
Imbruvica
Imfinzi
Imlygic
Inlyta
Inqovi
Inrebic
Iressa
Ixempra
Jakafi
Jelmyto
Jemperli
Jevtana
Kadcyla
Keytruda
Kisqali
Koselugo
Kymriah
Kyprolis
Lenvima
Levoleucovorin products (Fusilev, Khapzory, Levoleucovorin)
Libtayo
Lonsurf
Lorbrena
Lumakras

Lumoxiti					
Lynparza					
Margenza					
Mekinist					
Mektovi					
Monjuvi					
Mylotarg					
Nerlynx					
Nexavar					
Nilandron					
Ninlaro					
Nubeqa					
Odomzo					
Oncaspar					
Onivyde					
Onureg					
Opdivo					
Padcev					
Pemazyre					
Pepaxto					
Phesgo					
Piqray					
Polivy					
Pomalyst					
Portrazza					
Poteligeo					
Proleukin					
Qinlock					
Retevmo					
Revlimid					
Rituxan Hycela					
Romidepsin					
Rozlytrek					
Rubraca					
Rybrevant					
Rydapt					
Rylaze					
Sarclisa					
Sprycel					
Stivarga					
Sutent					
Sylatron					
Sylvant					
Synribo					
Tabrecta					
Tafinlar					
Tagrisso					
Talzenna					
Tarceva					
Targretin					
Tasigna					
Tazverik					
Tecartus					
Tecentriq					
Temodar (capsules)					
Tepadina					
Tepmetko					
Thalomid					
Tibsovo					
Torisel					
Trastuzumab					
Trodely					
Truseltiq					
Tukyasa					
Turalio					
Tykerb					

X

X

ESI Managed

Ukoniq							
Unituxin							
Valchlor							
Valstar							
Velcade, Bortezomib							
Venclexta							
Verzenio							
Vistogard							
Vitrakvi							
Vizimpro							
Votrient							
Vyxeos							
Wellreg							
Xalkori							
Xgeva							
Xospata							
Xpovio							
Xtandi							
Yervoy							
Yescarta							
Yonsa							
Zaltrap							
Zejula							
Zelboraf							
Zepzelca							
Zolinza							
Zydelig							
Zykadia							
Zynlonta							
Zytiga							
Proactive PA List - Full List Only	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Proactive PA List - Full List Only							
Arcalyst							
Austedo							
Beovu							
Bylvay							
Cablivi							
Chenodal							
Cinryze, Berinert							
Cosela							
Doptelet							
Empaveli							
Firazyr							
Givlaari							
Gocovi							
Haegarda							
Ilaris							
Ingrezza							
Isturisa							
Jynarque							
Kalbitor							
Korlym							
Krystexxa			X			X	ESI Managed
Kuvan							
Macular Degeneration (Eylea, Lucentis)							
Multipleta							
Nplate							
Nulibry							
Ocaliva							
Orladeyo							
Osmolex ER							
Oxervate							
Palyzqi							
Promacta							
Rezurock							
Ruconest							
Samsca							
Scenesse							
Signifor							
Takhzyro							
Tavalisse							
Tepezza							
Xenazine							
Xermelo							
Drug Quantity Management Ensure that the quantity of units supplied in each prescription remains consistent with clinical dosing guidelines and a Sponsor's benefit design. Note: List of drugs subject to change at the discretion of ESI. Automatic Updates to the below programs apply.	Fee - PMPM	In Place	Add	Remove	Continuation of Therapy (CoT)	PreNotify	Cov Review
Limited DQM List	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review

Limited DQM List			X			X	ESI Managed
Limited - default DQM per RX			X				
Allergies			X			X	ESI Managed
Anaphylaxis			X			X	ESI Managed
Anti-Infective			X			X	ESI Managed
Anti-Influenza			X			X	ESI Managed
Asthma/COPD			X			X	ESI Managed
Eye Conditions			X			X	ESI Managed
Hormone Supplementation			X			X	ESI Managed
Inflammatory Conditions			X			X	ESI Managed
Migraine Headaches			X			X	ESI Managed
Migraine Headaches - CGRP Products			X			X	ESI Managed
Nausea/Vomiting			X			X	ESI Managed
Oral Anti-fungals			X			X	ESI Managed
Pregnancy			X			X	ESI Managed
Sexual Disorders			X			X	ESI Managed
Sleep Disorder			X			X	ESI Managed
Topical Anti-fungals			X			X	ESI Managed
Topical Inflammatory Conditions			X			X	ESI Managed
Topical Pain			X			X	ESI Managed
Ulcer			X			X	ESI Managed
Wake Promoting Agents			X			X	ESI Managed
Contraceptives & Non-Pregnancy Related Products			X			X	ESI Managed
Advantage DQM list	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Advantage DQM List			X			X	ESI Managed
Anti-Infective - Specialty			X			X	ESI Managed
Asthma - Specialty			X			X	ESI Managed
Blood Disorders			X			X	ESI Managed
Bone Conditions			X			X	ESI Managed
Constipation			X			X	ESI Managed
Diabetes			X			X	ESI Managed
Diabetes - CGM Products			X			X	ESI Managed

Electrolyte Imbalance			X			X	ESI Managed
Endocrine/Rare			X			X	ESI Managed
Fertility			X			X	ESI Managed
Hepatitis C			X			X	ESI Managed
High Blood Cholesterol			X			X	ESI Managed
High Blood Pressure			X			X	ESI Managed
Inflammatory Conditions-Specialty			X			X	ESI Managed
Multiple Sclerosis			X			X	ESI Managed
Overactive Bladder			X			X	ESI Managed
Pain			X			X	ESI Managed
Pain - Narcotic			X			X	ESI Managed
Pulmonary Hypertension			X			X	ESI Managed
Respiratory Miscellaneous			X			X	ESI Managed
Wound Care			X			X	ESI Managed
Advantage Plus DQM List	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Advantage Plus DQM List			X			X	ESI Managed
Depression			X			X	ESI Managed
Heart Failure			X			X	ESI Managed
Mental/Neurological Disorders			X			X	ESI Managed
Oncology Package DQM List - Included in Oncology PA Package	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Alecensa							
Alunbrig							
Ayvakit							
Bosulif							
Braftovi							
Cabometyx							
Calquence							
Caprelsa							
Copiktra							
Cotellic							
Daurismo							
Erivedge							
Erleada							
Farydak							
Gilotrif							
Gleevec							
Ibrance							
Iclusig							
Idhifa							
Imbruvica							
Inlyta							
Inrebic							
Iressa							
Jakafi							
Kisqali							
Lorbrena							
Lynparza							
Mekinist							
Mektovi							

Nexavar			X			X	ESI Managed
Ninlaro							
Nubeqa							
Odomzo							
Pemazyre							
Qinlock							
Retevmo							
Rozlytrek							
Rubraca							
Sprycel							
Stivarga							
Sutent							
Tafinlar							
Tagrisso							
Talzenna							
Tarceva							
Tasigna							
Tukysa							
Turalio							
Tykerb							
Venclexta							
Verzenio							
Vizimpro							
Votrient							
Xalkori							
Xermelo							
Xtandi							
Yonsa							
Zejula							
Zelboraf							
Zydelig							
Zykadia							
Zytiga							
Step Therapy Intervene to support the use of less expensive and clinically appropriate medications at the point of service. Automatic Updates to the below programs apply.	Fee - PMPM	In Place	Add	Remove	Continuation of Therapy (CoT)	PreNotify	Cov Review
Limited Step Therapy List Note: all modules are available ala carte	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Limited Step Therapy List			X			X	ESI Managed
Default Version			X				
Atopic Dermatitis – Topical (CoT Available)			X			X	ESI Managed
Brexafemme (CoT Not Available)			X			X	ESI Managed
Carbinoxamine (CoT Available)			X			X	ESI Managed
Colchicine (CoT Not Available)			X			X	ESI Managed
COX-2 (CoT Available)			X			X	ESI Managed
Expendable Step (CoT Not Available)			X			X	ESI Managed
Hydrocortisone Acetate Suppository (CoT Available)			X			X	ESI Managed

Hypnotics (CoT Available)			X			X	ESI Managed
Lidocaine/Tetracaine (CoT Not Available)			X			X	ESI Managed
Nasal Steroid Preferred (Default/Preferred List)* (CoT Not Available)			X			X	ESI Managed
NSAID (CoT Available)			X			X	ESI Managed
Ophthalmic Antiallergy (CoT Available)			X			X	ESI Managed
Ophthalmic Corticosteroids (CoT Not Available)			X			X	ESI Managed
Ophthalmic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) (CoT Available)			X			X	ESI Managed
Phexxi (CoT Available)			X			X	ESI Managed
PPI (CoT available) (Zegerid - CoT not Available)			X			X	ESI Managed
Tetracyclines - Oral (CoT Available)			X			X	ESI Managed
Tolsura (CoT Available)			X			X	ESI Managed
Topical Acne/Rosacea (CoT Available)			X			X	ESI Managed
Topical Antibacterials (CoT Not Available)			X			X	ESI Managed
Topical Antifungals (CoT Available)			X			X	ESI Managed
Topical Corticosteroids (CoT Available)			X			X	ESI Managed
Topical Doxepin (CoT Not Available)			X			X	ESI Managed
Topical Prodrofilox Products (CoT Not Available)			X			X	ESI Managed
Topical Vitamin D (CoT Not Available)			X			X	ESI Managed
Advantage Step Therapy List	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Advantage Step Therapy List			X			X	ESI Managed
Default Version			X				
ARB (CoT Available)			X			X	ESI Managed
Avodart (CoT Available)			X			X	ESI Managed
Bisphosphonates (Enhanced) (CoT Available)			X			X	ESI Managed
Fenofibrate Preferred (Default/Preferred) (CoT Available)			X			X	ESI Managed
HMG (Generic) (CoT Available)			X			X	ESI Managed
Metformin (CoT Available)			X			X	ESI Managed
Methotrexate (CoT Available)			X			X	ESI Managed
Noctiva (CoT Not Available)			X			X	ESI Managed
Overactive Bladder Preferred (Default & Preferred List) (CoT Available)			X			X	ESI Managed
Saphnelo			X			X	ESI Managed
SGLT-2 Inhibitors (CoT Required) (Invokana, Invokamet, Invokamet XR CoT Not Available)			X		X		ESI Managed
SGLT-2/DPP-4 Combo (CoT Required)			X		X		ESI Managed
Thiazolidinedione (TZD) (CoT Required)			X		X		ESI Managed
Vitamin B12 (Generic) (CoT Available)			X			X	ESI Managed
Wake Promoting Agents (CoT Not Available)			X			X	ESI Managed
Advantage Plus Step Therapy list	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review

Advantage Plus Step Therapy List			X			X	ESI Managed
Default Version			X				
ADHD Non-Stimulant (CoT available)			X			X	ESI Managed
ADHD Stimulant (CoT available)			X			X	ESI Managed
Alzheimers (CoT required) (Namenda CoT not available)			X		X		ESI Managed
Antiepileptic Drugs (CoT required)			X		X		ESI Managed
Dronabinol (CoT not available)			X			X	ESI Managed
Gabapentin (CoT available) (Lyrica CR CoT not available)			X			X	ESI Managed
Gout (CoT available)			X			X	ESI Managed
Hydroxyurea Products (CoT not available)			X			X	ESI Managed
Migraine (CoT available)			X			X	ESI Managed
Naloxone injection (CoT not available)			X			X	ESI Managed
Opioid Induced Constipation (Preferred) (CoT not available)			X			X	ESI Managed
Other Antidepressants (CoT Required)			X		X		ESI Managed
Parkinson's Disease (MAO-B) (CoT available)			X			X	ESI Managed
Penicillamine (CoT not available)			X			X	ESI Managed
Pheochromocytoma (CoT not available)			X			X	ESI Managed
SSRI (CoT required)			X		X		ESI Managed
Topiramate (CoT available)			X			X	ESI Managed
Tramadol (CoT available)			X			X	ESI Managed
Veltassa (CoT not available)			X			X	ESI Managed
Preferred Specialty Management (PSM) List	Fee - PMPM	In Place	Add	Remove	CoT	PreNotify	Cov Review
Preferred Specialty Management (PSM) List			X			X	ESI Managed
Acromegaly			X			X	ESI Managed
Afinitor			X			X	ESI Managed
Alpha-1 Proteinase Inhibitors			X			X	ESI Managed
Bevacizumab			X			X	ESI Managed
Breast Cancer (Oral)			X			X	ESI Managed
Colony Stimulating Factors			X			X	ESI Managed
Cryopyrin-Associated Periodic Syndrome (CAPS)			X			X	ESI Managed
Cystic Fibrosis – Inhaled Tobramycin Products			X			X	ESI Managed
Erythroid Stimulants			X			X	ESI Managed
Gaucher's Disease			X			X	ESI Managed
Gleevec (also Included in Oncology Package)			X			X	ESI Managed
Growth Hormones			X			X	ESI Managed
Hemophilia (Recombinant Factor VIII)			X			X	ESI Managed
Hepatitis C - Oral			X			X	ESI Managed
Hereditary Angioedema			X			X	ESI Managed
Huntington's Disease and Movement Disorders-VMAT2.			X			X	ESI Managed

Imbruvica			X			X	ESI Managed
Infertility (COT required)			X		X		ESI Managed
Inflammatory Conditions			X			X	ESI Managed
Interleukin (IL)-5 Antagonists			X			X	ESI Managed
Iron Chelators			X			X	ESI Managed
Lambert-Eaton Myasthenic Syndrome (LEMS)			X			X	ESI Managed
Multiple Sclerosis			X			X	ESI Managed
Prostate Cancer GnRH Analogs			X			X	ESI Managed
Prostate Cancer (Oral)			X			X	ESI Managed
Pulmonary Arterial Hypertension (retiring 1/1/2022)			X			X	ESI Managed
Trastuzumab			X			X	ESI Managed
Summary	Fee - PMPM	In Place	Add	Remove			
New Total Drug Choices UM Program Fee: Discount applied	\$ 1.06 PMPM		X			X	

Note:

- 1) Prices for new modules will be established upon development.
- 2) Criteria for modules are subject to change at the discretion of ESI.

Clinical Programs

Express Scripts (ESI) offers a comprehensive suite of trend and integrated health management programs. This offering may change or be discontinued from time to time as we update our offering to meet the needs of the marketplace.

Advanced Opioid Management	Fee PMPM	In Place	Add	Remove	Pre Notify	Coverage Review
Advanced Opioid Management: <ul style="list-style-type: none"> • Proactive Opioid Member Education Letter • Opioid Neuroscience Pharmacist Outreach (TRC) • Opioid & Opioid Adjacent (benzodiazepine, gabapentin & select muscle relaxants) Physician Care Alerts • Drug Deactivation Disposal Bags • Enhanced FWA (choose option below) • Enhanced Prior Authorization (Long Acting Opioids) • First Fill - 7 Days' Supply Limit for adults (Short Acting Opioids) on the first 4 fills; not to exceed a 28-days' supply in a 60-day period • First Fill - 3 Days' Supply Limit for pediatric patients (Short Acting Opioids) for the first 4 fills; not to exceed a 12-days' supply in a 60-day period <ul style="list-style-type: none"> • Morphine Equivalent Dose Edit (MEQD) 90 MME for new starts • Morphine Equivalent Dose Edit (MEQD) 200 MME for existing utilizer • Fentanyl patches – (DQM) • Enhanced Prior Auth (Fentanyl TIRF) • Benzodiazepines (DQM) • Gabapentin (DQM) • Select Muscle Relaxants (DQM) • Prescriber Education & Peer Comparison 	\$0.39 PMPM		X			ESI managed
Advanced Opioid Management FWA eFWA enrollment option as part of Advanced Opioid Managed Program Note: lock-in overturn reviews are administrative, not clinical, in nature.		In Place	Add	Remove		
			X			